Women's Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) - Global forecast to 2024
“Growing incidence of chronic health conditions among women and the demand in contraceptives to prevent unintended pregnancies are the key factors driving the women’s healthcare market.”
The global women’s healthcare market is projected to reach USD 17.8 billion by 2024 from USD 9.6 billion in 2019, at a CAGR of 13.2% during the forecast period. Growth in this market is mainly driven by the growing incidence of chronic health conditions among women, growing demand for contraceptives to prevent unintended pregnancies, growing focus on R&D by key players for the development of advanced products, and the government initiatives to curb population growth. On the other hand, the reluctance to use contraceptives is a major factor limiting the market growth.
“Prolia is the largest and fastest-growing segment of the market.”
On the basis of drug, the women’s healthcare market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28). Prolia is the largest and fastest-growing segment of the market. The increasing unit demand for prolia due to the high prevalence of postmenopausal osteoporosis among women in the US is one of the major factors responsible for the large share and high growth rate of this drug.
“The postmenopausal osteoporosis segment accounted for the largest share in 2019.”
Based on application, the women’s healthcare market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, PCOS, and other applications. The postmenopausal osteoporosis segment accounted for the largest share of the women’s healthcare market in 2018. The growing prevalence of postmenopausal osteoporosis and the focus of pharmaceutical players on providing effective drugs for the treatment of postmenopausal osteoporosis are some of the key factors supporting the growth of this segment. This segment is also expected to register the highest CAGR during the forecast period.
“North America to be the largest and the fastest-growing regional market.”
North America, which comprises the US and Canada, forms the largest market for women’s healthcare. Growing awareness and understanding regarding contraceptives among American women, easy access to modern contraception as compared to developing countries, and increased healthcare spending are some of the major factors responsible for the large share and high growth of this market. Additionally, the increasing median age of first-time pregnancies and the growing prevalence of PCOS & postmenopausal osteoporosis also propels the market growth in this region.
The primary interviews conducted for this report can be categorized as follows:
This report provides a study of the women’s healthcare market. It aims at estimating the size and future growth potential of the market across different segments, such as drug, application, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall women’s healthcare market and its subsegments. This report will also help stakeholders understand the competitive landscape, and gain insights to position their business better and make suitable go-to-market strategies. It will also enable stakeholders to gauge the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.
The global women’s healthcare market is projected to reach USD 17.8 billion by 2024 from USD 9.6 billion in 2019, at a CAGR of 13.2% during the forecast period. Growth in this market is mainly driven by the growing incidence of chronic health conditions among women, growing demand for contraceptives to prevent unintended pregnancies, growing focus on R&D by key players for the development of advanced products, and the government initiatives to curb population growth. On the other hand, the reluctance to use contraceptives is a major factor limiting the market growth.
“Prolia is the largest and fastest-growing segment of the market.”
On the basis of drug, the women’s healthcare market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28). Prolia is the largest and fastest-growing segment of the market. The increasing unit demand for prolia due to the high prevalence of postmenopausal osteoporosis among women in the US is one of the major factors responsible for the large share and high growth rate of this drug.
“The postmenopausal osteoporosis segment accounted for the largest share in 2019.”
Based on application, the women’s healthcare market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, PCOS, and other applications. The postmenopausal osteoporosis segment accounted for the largest share of the women’s healthcare market in 2018. The growing prevalence of postmenopausal osteoporosis and the focus of pharmaceutical players on providing effective drugs for the treatment of postmenopausal osteoporosis are some of the key factors supporting the growth of this segment. This segment is also expected to register the highest CAGR during the forecast period.
“North America to be the largest and the fastest-growing regional market.”
North America, which comprises the US and Canada, forms the largest market for women’s healthcare. Growing awareness and understanding regarding contraceptives among American women, easy access to modern contraception as compared to developing countries, and increased healthcare spending are some of the major factors responsible for the large share and high growth of this market. Additionally, the increasing median age of first-time pregnancies and the growing prevalence of PCOS & postmenopausal osteoporosis also propels the market growth in this region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 (41%), Tier 2 (31%), and Tier 3 (28%)
- By Designation: C-level (33%), D-level (29%), and Others (38%)
- By Region: North America (58%), Europe (19%), Asia (14%), and the RoW (9%)
- Bayer AG (Germany)
- Allergan (Dublin)
- Merck & Co. (US)
- Pfizer Inc. (US)
- Amgen (US)
- Agile Therapeutics Inc. (US)
- Ferring Pharmaceuticals (US)
- Mylan N.V. (US)
- Lupin (India)
- Blairex Laboratories (US)
- Apothecus Pharmaceutical (US)
- Eli Lilly And Company (US)
- Novartis AG (Switzerland)
- Johnson & Johnson (US)
This report provides a study of the women’s healthcare market. It aims at estimating the size and future growth potential of the market across different segments, such as drug, application, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall women’s healthcare market and its subsegments. This report will also help stakeholders understand the competitive landscape, and gain insights to position their business better and make suitable go-to-market strategies. It will also enable stakeholders to gauge the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY SOURCES
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.2 MARKET SIZE ESTIMATIONS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 WOMEN’S HEALTHCARE MARKET OVERVIEW
4.2 WOMEN’S HEALTHCARE MARKET, BY DRUG (2019–2024)
4.3 WOMEN’S HEALTHCARE MARKET, BY APPLICATION (2019 VS. 2024)
4.4 WOMEN’S HEALTHCARE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MARKET DRIVERS
5.2.1.1 Growing incidence of chronic health conditions among women
5.2.1.2 Demand for contraceptives to prevent unintended pregnancies
5.2.1.3 Government initiatives to curb population growth
5.2.1.4 Growing focus on product R&D
5.2.2 MARKET OPPORTUNITIES
5.2.2.1 Emerging markets
5.2.3 MARKET CHALLENGES
5.2.3.1 Reluctance to use contraceptives
6 WOMEN’S HEALTHCARE MARKET, BY DRUG
6.1 INTRODUCTION
6.2 PROLIA
6.2.1 PROLIA ACCOUNTS FOR THE LARGEST SHARE OF THE WOMEN’S HEALTHCARE MARKET
6.3 XGEVA
6.3.1 XGEVA IS PRIMARILY MARKETED IN THE US AND EUROPEAN COUNTRIES
6.4 FORTEO
6.4.1 ELI LILLY IS EXPECTED TO EXPERIENCE A REVENUE DECLINE IN THE COMING YEARS DUE TO THE PATENT EXPIRY OF FORTEO
6.5 MIRENA
6.5.1 MIRENA IS WIDELY ACCEPTED AMONGST END USERS OWING TO THE MINIMAL SIDE-EFFECTS ASSOCIATED WITH IT
6.6 NUVARING
6.6.1 NUVARING IS ONE OF THE TOP-SELLING DRUGS FROM MERCK IN THE WOMEN’S HEALTH CATEGORY
6.7 PREMARIN
6.7.1 PREMARIN IS USED FOR THE TREATMENT OF OSTEOPOROSIS IN WOMEN
6.8 ORTHO TRI-CY LO (28)
6.8.1 GROWING NUMBER OF ANDA TO MARKET GENERIC VERSIONS OF ORTHO TRI-CY LO (28) TO HAMPER ITS SALES IN THE COMING YEARS
6.9 EVISTA
6.9.1 INTENSE GENERIC COMPETITION HAS LED TO A YEAR-ON-YEAR DECLINE IN EVISTA’S SALES
6.10 RECLAST/ACLASTA
6.10.1 ACLASTA HAS MORE BENEFITS AS COMPARED TO OTHER DRUGS
6.11 ZOMETA
6.11.1 EARLY PATENT EXPIRY OF ZOMETA IN THE US AND EUROPE HAS AFFECTED ITS SALES
6.12 MINASTRIN 24 FE
6.12.1 AVAILABILITY OF LOW-PRICED GENERIC VERSIONS OF MINASTRIN 24 FE IS ONE OF THE MAIN REASONS FOR THE LOWER SALES OF THIS DRUG
6.13 ACTONEL
6.13.1 INTENSE COMPETITION IN THE OSTEOPOROSIS MARKET HAS LED TO A SALES DECLINE IN ACTONEL IN THE LAST FEW YEARS
6.14 PIPELINE DRUGS
7 WOMEN’S HEALTHCARE MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 POSTMENOPAUSAL OSTEOPOROSIS
7.2.1 HIGH PREVALENCE OF OSTEOPOROSIS IN WOMEN HAS PROMPTED COMPANIES TO FOCUS ON THIS THERAPEUTIC AREA
7.3 CONTRACEPTIVES
7.3.1 BENEFITS OFFERED BY CONTRACEPTIVES DRIVING THEIR DEMAND AMONG END USERS
7.4 MENOPAUSE
7.4.1 DEMAND FOR NON-HORMONAL THERAPIES HAS INCREASED OVER THE LAST FEW YEARS
7.5 HORMONAL INFERTILITY
7.5.1 INCREASING AWARENESS ABOUT OVULATION HEALTH TO SUPPORT MARKET GROWTH
7.6 POLYCYSTIC OVARY SYNDROME
7.6.1 GROWING PREVALENCE OF PCOS IS RESPONSIBLE FOR MARKET GROWTH
7.7 ENDOMETRIOSIS
7.7.1 ORILISSA IS THE FIRST AND ONLY ORAL TREATMENT SPECIFICALLY AVAILABLE FOR WOMEN WITH ENDOMETRIOSIS PAIN
7.8 OTHER APPLICATIONS
8 WOMEN’S HEALTHCARE MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 US
8.2.1.1 Strong economy and high contraception awareness are key factors driving market growth in the US
8.2.2 CANADA
8.2.2.1 Growing prevalence of PCOS and obesity to support market growth in Canada
8.3 EUROPE
8.3.1 GERMANY
8.3.1.1 Germany holds the largest share of the women’s healthcare market in Europe
8.3.2 UK
8.3.2.1 Government support and favorable training programs are major market drivers in the UK
8.3.3 FRANCE
8.3.3.1 High prevalence of lifestyle disorders among women in France to support market growth
8.3.4 ITALY
8.3.4.1 Relatively high awareness of contraceptives to drive market growth in Italy
8.3.5 SPAIN
8.3.5.1 Improved healthcare expenditure to support the market in Spain
8.3.6 REST OF EUROPE
8.4 ASIA PACIFIC
8.4.1 JAPAN
8.4.1.1 Japan dominates the APAC market for women’s healthcare
8.4.2 CHINA
8.4.2.1 Growing population and urbanization are factors responsible for the growth of the market in China
8.4.3 INDIA
8.4.3.1 Increasing government initiatives to curb population growth will drive market growth in India
8.4.4 REST OF APAC
8.5 LATIN AMERICA
8.5.1 INCREASING LIFESTYLE DISEASES AND AWARENESS AMONG WOMEN TO DRIVE MARKET GROWTH IN LATIN AMERICA
8.6 MIDDLE EAST & AFRICA
8.6.1 INCREASING GOVERNMENT INITIATIVES TO CURB POPULATION GROWTH WILL DRIVE MARKET GROWTH IN INDIA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 MARKET SHARE ANALYSIS
9.3 COMPETITIVE LEADERSHIP MAPPING
9.3.1 VISIONARY LEADERS
9.3.2 DYNAMIC DIFFERENTIATORS
9.3.3 INNOVATORS
9.3.4 EMERGING COMPANIES
10 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
10.1 AMGEN
10.2 BAYER AG
10.3 ELI LILLY AND COMPANY
10.4 MERCK & CO.
10.5 PFIZER
10.6 ALLERGAN
10.7 JOHNSON & JOHNSON SERVICES INC.
10.8 NOVARTIS AG
10.9 MYLAN NV
10.10 LUPIN LIMITED
10.11 AGILE THERAPEUTICS
10.12 FERRING PHARMACEUTICALS
10.13 BLAIREX LABORATORIES, INC.
10.14 APOTHECUS PHARMACEUTICAL CORPORATION
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
11 APPENDIX
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 AVAILABLE CUSTOMIZATIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY SOURCES
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.2 MARKET SIZE ESTIMATIONS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 WOMEN’S HEALTHCARE MARKET OVERVIEW
4.2 WOMEN’S HEALTHCARE MARKET, BY DRUG (2019–2024)
4.3 WOMEN’S HEALTHCARE MARKET, BY APPLICATION (2019 VS. 2024)
4.4 WOMEN’S HEALTHCARE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MARKET DRIVERS
5.2.1.1 Growing incidence of chronic health conditions among women
5.2.1.2 Demand for contraceptives to prevent unintended pregnancies
5.2.1.3 Government initiatives to curb population growth
5.2.1.4 Growing focus on product R&D
5.2.2 MARKET OPPORTUNITIES
5.2.2.1 Emerging markets
5.2.3 MARKET CHALLENGES
5.2.3.1 Reluctance to use contraceptives
6 WOMEN’S HEALTHCARE MARKET, BY DRUG
6.1 INTRODUCTION
6.2 PROLIA
6.2.1 PROLIA ACCOUNTS FOR THE LARGEST SHARE OF THE WOMEN’S HEALTHCARE MARKET
6.3 XGEVA
6.3.1 XGEVA IS PRIMARILY MARKETED IN THE US AND EUROPEAN COUNTRIES
6.4 FORTEO
6.4.1 ELI LILLY IS EXPECTED TO EXPERIENCE A REVENUE DECLINE IN THE COMING YEARS DUE TO THE PATENT EXPIRY OF FORTEO
6.5 MIRENA
6.5.1 MIRENA IS WIDELY ACCEPTED AMONGST END USERS OWING TO THE MINIMAL SIDE-EFFECTS ASSOCIATED WITH IT
6.6 NUVARING
6.6.1 NUVARING IS ONE OF THE TOP-SELLING DRUGS FROM MERCK IN THE WOMEN’S HEALTH CATEGORY
6.7 PREMARIN
6.7.1 PREMARIN IS USED FOR THE TREATMENT OF OSTEOPOROSIS IN WOMEN
6.8 ORTHO TRI-CY LO (28)
6.8.1 GROWING NUMBER OF ANDA TO MARKET GENERIC VERSIONS OF ORTHO TRI-CY LO (28) TO HAMPER ITS SALES IN THE COMING YEARS
6.9 EVISTA
6.9.1 INTENSE GENERIC COMPETITION HAS LED TO A YEAR-ON-YEAR DECLINE IN EVISTA’S SALES
6.10 RECLAST/ACLASTA
6.10.1 ACLASTA HAS MORE BENEFITS AS COMPARED TO OTHER DRUGS
6.11 ZOMETA
6.11.1 EARLY PATENT EXPIRY OF ZOMETA IN THE US AND EUROPE HAS AFFECTED ITS SALES
6.12 MINASTRIN 24 FE
6.12.1 AVAILABILITY OF LOW-PRICED GENERIC VERSIONS OF MINASTRIN 24 FE IS ONE OF THE MAIN REASONS FOR THE LOWER SALES OF THIS DRUG
6.13 ACTONEL
6.13.1 INTENSE COMPETITION IN THE OSTEOPOROSIS MARKET HAS LED TO A SALES DECLINE IN ACTONEL IN THE LAST FEW YEARS
6.14 PIPELINE DRUGS
7 WOMEN’S HEALTHCARE MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 POSTMENOPAUSAL OSTEOPOROSIS
7.2.1 HIGH PREVALENCE OF OSTEOPOROSIS IN WOMEN HAS PROMPTED COMPANIES TO FOCUS ON THIS THERAPEUTIC AREA
7.3 CONTRACEPTIVES
7.3.1 BENEFITS OFFERED BY CONTRACEPTIVES DRIVING THEIR DEMAND AMONG END USERS
7.4 MENOPAUSE
7.4.1 DEMAND FOR NON-HORMONAL THERAPIES HAS INCREASED OVER THE LAST FEW YEARS
7.5 HORMONAL INFERTILITY
7.5.1 INCREASING AWARENESS ABOUT OVULATION HEALTH TO SUPPORT MARKET GROWTH
7.6 POLYCYSTIC OVARY SYNDROME
7.6.1 GROWING PREVALENCE OF PCOS IS RESPONSIBLE FOR MARKET GROWTH
7.7 ENDOMETRIOSIS
7.7.1 ORILISSA IS THE FIRST AND ONLY ORAL TREATMENT SPECIFICALLY AVAILABLE FOR WOMEN WITH ENDOMETRIOSIS PAIN
7.8 OTHER APPLICATIONS
8 WOMEN’S HEALTHCARE MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 US
8.2.1.1 Strong economy and high contraception awareness are key factors driving market growth in the US
8.2.2 CANADA
8.2.2.1 Growing prevalence of PCOS and obesity to support market growth in Canada
8.3 EUROPE
8.3.1 GERMANY
8.3.1.1 Germany holds the largest share of the women’s healthcare market in Europe
8.3.2 UK
8.3.2.1 Government support and favorable training programs are major market drivers in the UK
8.3.3 FRANCE
8.3.3.1 High prevalence of lifestyle disorders among women in France to support market growth
8.3.4 ITALY
8.3.4.1 Relatively high awareness of contraceptives to drive market growth in Italy
8.3.5 SPAIN
8.3.5.1 Improved healthcare expenditure to support the market in Spain
8.3.6 REST OF EUROPE
8.4 ASIA PACIFIC
8.4.1 JAPAN
8.4.1.1 Japan dominates the APAC market for women’s healthcare
8.4.2 CHINA
8.4.2.1 Growing population and urbanization are factors responsible for the growth of the market in China
8.4.3 INDIA
8.4.3.1 Increasing government initiatives to curb population growth will drive market growth in India
8.4.4 REST OF APAC
8.5 LATIN AMERICA
8.5.1 INCREASING LIFESTYLE DISEASES AND AWARENESS AMONG WOMEN TO DRIVE MARKET GROWTH IN LATIN AMERICA
8.6 MIDDLE EAST & AFRICA
8.6.1 INCREASING GOVERNMENT INITIATIVES TO CURB POPULATION GROWTH WILL DRIVE MARKET GROWTH IN INDIA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 MARKET SHARE ANALYSIS
9.3 COMPETITIVE LEADERSHIP MAPPING
9.3.1 VISIONARY LEADERS
9.3.2 DYNAMIC DIFFERENTIATORS
9.3.3 INNOVATORS
9.3.4 EMERGING COMPANIES
10 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
10.1 AMGEN
10.2 BAYER AG
10.3 ELI LILLY AND COMPANY
10.4 MERCK & CO.
10.5 PFIZER
10.6 ALLERGAN
10.7 JOHNSON & JOHNSON SERVICES INC.
10.8 NOVARTIS AG
10.9 MYLAN NV
10.10 LUPIN LIMITED
10.11 AGILE THERAPEUTICS
10.12 FERRING PHARMACEUTICALS
10.13 BLAIREX LABORATORIES, INC.
10.14 APOTHECUS PHARMACEUTICAL CORPORATION
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
11 APPENDIX
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 AVAILABLE CUSTOMIZATIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 2 PROLIA: PRODUCT HIGHLIGHTS
TABLE 3 WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY REGION, 2017–2024 (USD MILLION)
TABLE 4 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 5 EUROPE: WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 6 APAC: WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 7 XGEVA: PRODUCT HIGHLIGHTS
TABLE 8 WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY REGION, 2017–2024 (USD MILLION)
TABLE 9 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 10 EUROPE: WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 11 APAC: WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 12 FORTEO: PRODUCT HIGHLIGHTS
TABLE 13 WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY REGION, 2017–2024 (USD MILLION)
TABLE 14 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 15 EUROPE: WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 16 APAC: WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 17 MIRENA: PRODUCT HIGHLIGHTS
TABLE 18 WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY REGION, 2017–2024 (USD MILLION)
TABLE 19 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 20 EUROPE: WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 21 APAC: WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 22 NUVARING: PRODUCT HIGHLIGHTS
TABLE 23 WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY REGION, 2017–2024 (USD MILLION)
TABLE 24 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 25 EUROPE: WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 26 APAC: WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 27 PREMARIN: PRODUCT HIGHLIGHTS
TABLE 28 WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY REGION, 2017–2024 (USD MILLION)
TABLE 29 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 30 EUROPE: WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 31 APAC: WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 32 ORTHO TRI-CY LO (28): PRODUCT HIGHLIGHTS
TABLE 33 WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28), BY REGION, 2017–2024 (USD MILLION)
TABLE 34 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28), BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 35 EUROPE: WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28), BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 36 APAC: WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28), BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 37 EVISTA: PRODUCT HIGHLIGHTS
TABLE 38 WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY REGION, 2017–2024 (USD MILLION)
TABLE 39 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 40 EUROPE: WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 41 APAC: WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 42 RECLAST/ACLASTA: PRODUCT HIGHLIGHTS
TABLE 43 WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA, BY REGION, 2017–2024 (USD MILLION)
TABLE 44 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 45 EUROPE: WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 46 APAC: WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 47 ZOMETA: PRODUCT HIGHLIGHTS
TABLE 48 WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY REGION, 2017–2024 (USD MILLION)
TABLE 49 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 50 EUROPE: WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 51 APAC: WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 52 MINASTRIN 24 FE: PRODUCT HIGHLIGHTS
TABLE 53 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR MINASTRIN 24 FE, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 54 ACTONEL: PRODUCT HIGHLIGHTS
TABLE 55 WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY REGION, 2017–2024 (USD MILLION)
TABLE 56 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 57 EUROPE: WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 58 APAC: WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 59 INDICATIVE LIST OF DRUGS IN PHASE III
TABLE 60 WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 61 WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY REGION, 2017–2024 (USD MILLION)
TABLE 62 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 63 EUROPE: WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 64 APAC: WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 65 WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY REGION, 2017–2024 (USD MILLION)
TABLE 66 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 67 EUROPE: WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 68 APAC: WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 69 WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY REGION, 2017–2024 (USD MILLION)
TABLE 70 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 71 EUROPE: WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 72 APAC: WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 73 WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY, BY REGION, 2017–2024 (USD MILLION)
TABLE 74 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 75 EUROPE: WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 76 APAC: WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 77 WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME, BY REGION, 2017–2024 (USD MILLION)
TABLE 78 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 79 EUROPE: WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME, BY COUNTRY, 2017–2024 (USD THOUSAND)
TABLE 80 APAC: WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 81 WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY REGION, 2017–2024 (USD MILLION)
TABLE 82 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 83 EUROPE: WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY COUNTRY, 2017–2024 (USD THOUSAND)
TABLE 84 APAC: WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 85 WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS, BY REGION, 2017–2024 (USD MILLION)
TABLE 86 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 87 EUROPE: WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 88 APAC: WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 89 WOMEN’S HEALTHCARE MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 90 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 91 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 92 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 93 US: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 94 US: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 95 CANADA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 96 CANADA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 97 EUROPE: WOMEN’S HEALTHCARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 98 EUROPE: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 99 EUROPE: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 100 GERMANY: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 101 GERMANY: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 102 UK: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 103 UK: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 104 FRANCE: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 105 FRANCE: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 106 ITALY: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 107 ITALY: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 108 SPAIN: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 109 SPAIN: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD THOUSAND)
TABLE 110 ROE: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 111 ROE: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 112 ASIA PACIFIC: WOMEN’S HEALTHCARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 113 ASIA PACIFIC: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 114 ASIA PACIFIC: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 115 JAPAN: INDICATIVE LIST OF CONFERENCES
TABLE 116 JAPAN: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 117 JAPAN: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 118 CHINA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 119 CHINA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 120 INDIA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 121 INDIA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 122 ROAPAC: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 123 ROAPAC: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 124 LATIN AMERICA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 125 LATIN AMERICA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 126 MIDDLE EAST & AFRICA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 127 MIDDLE EAST & AFRICA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 1 WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 2 PROLIA: PRODUCT HIGHLIGHTS
TABLE 3 WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY REGION, 2017–2024 (USD MILLION)
TABLE 4 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 5 EUROPE: WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 6 APAC: WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 7 XGEVA: PRODUCT HIGHLIGHTS
TABLE 8 WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY REGION, 2017–2024 (USD MILLION)
TABLE 9 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 10 EUROPE: WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 11 APAC: WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 12 FORTEO: PRODUCT HIGHLIGHTS
TABLE 13 WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY REGION, 2017–2024 (USD MILLION)
TABLE 14 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 15 EUROPE: WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 16 APAC: WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 17 MIRENA: PRODUCT HIGHLIGHTS
TABLE 18 WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY REGION, 2017–2024 (USD MILLION)
TABLE 19 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 20 EUROPE: WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 21 APAC: WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 22 NUVARING: PRODUCT HIGHLIGHTS
TABLE 23 WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY REGION, 2017–2024 (USD MILLION)
TABLE 24 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 25 EUROPE: WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 26 APAC: WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 27 PREMARIN: PRODUCT HIGHLIGHTS
TABLE 28 WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY REGION, 2017–2024 (USD MILLION)
TABLE 29 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 30 EUROPE: WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 31 APAC: WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 32 ORTHO TRI-CY LO (28): PRODUCT HIGHLIGHTS
TABLE 33 WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28), BY REGION, 2017–2024 (USD MILLION)
TABLE 34 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28), BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 35 EUROPE: WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28), BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 36 APAC: WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28), BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 37 EVISTA: PRODUCT HIGHLIGHTS
TABLE 38 WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY REGION, 2017–2024 (USD MILLION)
TABLE 39 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 40 EUROPE: WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 41 APAC: WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 42 RECLAST/ACLASTA: PRODUCT HIGHLIGHTS
TABLE 43 WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA, BY REGION, 2017–2024 (USD MILLION)
TABLE 44 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 45 EUROPE: WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 46 APAC: WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 47 ZOMETA: PRODUCT HIGHLIGHTS
TABLE 48 WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY REGION, 2017–2024 (USD MILLION)
TABLE 49 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 50 EUROPE: WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 51 APAC: WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 52 MINASTRIN 24 FE: PRODUCT HIGHLIGHTS
TABLE 53 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR MINASTRIN 24 FE, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 54 ACTONEL: PRODUCT HIGHLIGHTS
TABLE 55 WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY REGION, 2017–2024 (USD MILLION)
TABLE 56 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 57 EUROPE: WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 58 APAC: WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 59 INDICATIVE LIST OF DRUGS IN PHASE III
TABLE 60 WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 61 WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY REGION, 2017–2024 (USD MILLION)
TABLE 62 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 63 EUROPE: WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 64 APAC: WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 65 WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY REGION, 2017–2024 (USD MILLION)
TABLE 66 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 67 EUROPE: WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 68 APAC: WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 69 WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY REGION, 2017–2024 (USD MILLION)
TABLE 70 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 71 EUROPE: WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 72 APAC: WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 73 WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY, BY REGION, 2017–2024 (USD MILLION)
TABLE 74 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 75 EUROPE: WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 76 APAC: WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 77 WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME, BY REGION, 2017–2024 (USD MILLION)
TABLE 78 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 79 EUROPE: WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME, BY COUNTRY, 2017–2024 (USD THOUSAND)
TABLE 80 APAC: WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 81 WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY REGION, 2017–2024 (USD MILLION)
TABLE 82 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 83 EUROPE: WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY COUNTRY, 2017–2024 (USD THOUSAND)
TABLE 84 APAC: WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 85 WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS, BY REGION, 2017–2024 (USD MILLION)
TABLE 86 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 87 EUROPE: WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 88 APAC: WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 89 WOMEN’S HEALTHCARE MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 90 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 91 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 92 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 93 US: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 94 US: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 95 CANADA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 96 CANADA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 97 EUROPE: WOMEN’S HEALTHCARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 98 EUROPE: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 99 EUROPE: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 100 GERMANY: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 101 GERMANY: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 102 UK: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 103 UK: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 104 FRANCE: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 105 FRANCE: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 106 ITALY: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 107 ITALY: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 108 SPAIN: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 109 SPAIN: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD THOUSAND)
TABLE 110 ROE: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 111 ROE: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 112 ASIA PACIFIC: WOMEN’S HEALTHCARE MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 113 ASIA PACIFIC: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 114 ASIA PACIFIC: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 115 JAPAN: INDICATIVE LIST OF CONFERENCES
TABLE 116 JAPAN: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 117 JAPAN: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 118 CHINA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 119 CHINA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 120 INDIA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 121 INDIA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 122 ROAPAC: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 123 ROAPAC: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 124 LATIN AMERICA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 125 LATIN AMERICA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 126 MIDDLE EAST & AFRICA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 127 MIDDLE EAST & AFRICA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 3 BOTTOM-UP APPROACH
FIGURE 4 TOP-DOWN APPROACH
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 WOMEN’S HEALTHCARE MARKET, BY DRUG, 2019 VS. 2024 (USD MILLION)
FIGURE 7 WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2019 VS. 2024 (USD MILLION)
FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE WOMEN’S HEALTHCARE MARKET
FIGURE 9 GROWING INCIDENCE OF CHRONIC HEALTH CONDITIONS AMONG WOMEN IS A MAJOR FACTOR DRIVING THE WOMEN’S HEALTHCARE MARKET
FIGURE 10 PROLIA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 11 POSTMENOPAUSAL OSTEOPOROSIS TO DOMINATE THE WOMEN’S HEALTHCARE APPLICATIONS MARKET DURING THE FORECAST PERIOD
FIGURE 12 NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR WOMEN’S HEALTHCARE PRODUCTS
FIGURE 13 WOMEN’S HEALTHCARE MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET SNAPSHOT
FIGURE 15 EUROPE: WOMEN’S HEALTHCARE MARKET SNAPSHOT
FIGURE 16 WOMEN’S HEALTHCARE MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
FIGURE 17 COMPETITIVE LEADERSHIP MAPPING OF THE WOMEN’S HEALTHCARE
MARKET, 2018
FIGURE 18 AMGEN: COMPANY SNAPSHOT
FIGURE 19 BAYER AG: COMPANY SNAPSHOT
FIGURE 20 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
FIGURE 21 MERCK & CO.: COMPANY SNAPSHOT
FIGURE 22 PFIZER: COMPANY SNAPSHOT
FIGURE 23 ALLERGAN: COMPANY SNAPSHOT
FIGURE 24 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
FIGURE 25 NOVARTIS AG: COMPANY SNAPSHOT
FIGURE 26 MYLAN NV: COMPANY SNAPSHOT
FIGURE 27 LUPIN LIMITED: COMPANY SNAPSHOT
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 3 BOTTOM-UP APPROACH
FIGURE 4 TOP-DOWN APPROACH
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 WOMEN’S HEALTHCARE MARKET, BY DRUG, 2019 VS. 2024 (USD MILLION)
FIGURE 7 WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2019 VS. 2024 (USD MILLION)
FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE WOMEN’S HEALTHCARE MARKET
FIGURE 9 GROWING INCIDENCE OF CHRONIC HEALTH CONDITIONS AMONG WOMEN IS A MAJOR FACTOR DRIVING THE WOMEN’S HEALTHCARE MARKET
FIGURE 10 PROLIA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 11 POSTMENOPAUSAL OSTEOPOROSIS TO DOMINATE THE WOMEN’S HEALTHCARE APPLICATIONS MARKET DURING THE FORECAST PERIOD
FIGURE 12 NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR WOMEN’S HEALTHCARE PRODUCTS
FIGURE 13 WOMEN’S HEALTHCARE MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET SNAPSHOT
FIGURE 15 EUROPE: WOMEN’S HEALTHCARE MARKET SNAPSHOT
FIGURE 16 WOMEN’S HEALTHCARE MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
FIGURE 17 COMPETITIVE LEADERSHIP MAPPING OF THE WOMEN’S HEALTHCARE
MARKET, 2018
FIGURE 18 AMGEN: COMPANY SNAPSHOT
FIGURE 19 BAYER AG: COMPANY SNAPSHOT
FIGURE 20 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
FIGURE 21 MERCK & CO.: COMPANY SNAPSHOT
FIGURE 22 PFIZER: COMPANY SNAPSHOT
FIGURE 23 ALLERGAN: COMPANY SNAPSHOT
FIGURE 24 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
FIGURE 25 NOVARTIS AG: COMPANY SNAPSHOT
FIGURE 26 MYLAN NV: COMPANY SNAPSHOT
FIGURE 27 LUPIN LIMITED: COMPANY SNAPSHOT
